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Background-—Genome-wide association studies identiﬁed ADAMTS7 as a risk locus for coronary artery disease (CAD). Functional
studies suggest that ADAMTS7 may promote cellular processes in atherosclerosis. We sought to examine the association between
genetic variation at ADAMTS7 and measures of atherosclerosis using histological, angiographic, and clinical outcomes data.
Methods and Results-—The lead CAD-associated single-nucleotide polymorphism rs3825807 at the ADAMTS7 locus was
genotyped. The G allele (reduced ADAMTS7 function) was associated with a smaller ﬁbrous cap (P=0.017) and a smaller
percentage area of a-actin (smooth muscle cell marker) in the intima (P=0.017), but was not associated with calciﬁcation or plaque
thickness, following ex vivo immunohistochemistry analysis of human coronary plaques (n=50; mean age 72.211.3). In two
independent cohorts (Southampton Atherosclerosis Study [n=1359; mean age 62.510.3; 70.1% men] and the Emory
Cardiovascular Biobank [EmCAB; n=2684; mean age 63.811.3; 68.7% men]), the G allele was associated with 16% to 19% lower
odds of obstructive CAD (Southampton Atherosclerosis Study: odds ratio, 0.81; 95% conﬁdence interval, 0.67–0.98; EmCAB: odds
ratio, 0.84; 95% conﬁdence interval, 0.75–0.95) with similar effects for multivessel, left anterior descending, and proximal CAD.
Furthermore, each copy of the G allele was associated with lower angiographic severity Gensini score (Southampton
Atherosclerosis Study, P=0.026; EmCAB, P<0.001), lower Sullivan Extent score (Southampton Atherosclerosis Study, P=0.029;
EmCAB, P<0.001), and a 23% lower risk of incident revascularization procedures (EmCAB: hazard ratio, 0.76; 95% conﬁdence
interval, 0.59–0.98). There were no associations with all-cause mortality or incident myocardial infarction.
Conclusions-—Genetic variation at the ADAMTS7 locus is associated with several complementary CAD phenotypes, supporting the
emerging role of ADAMTS7 in atherosclerosis and may represent a potential drug target. ( J Am Heart Assoc. 2017;6:e006928.
DOI: 10.1161/JAHA.117.006928.)
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G enome-wide association studies have revealed a robustassociation between genetic variation in the ADAMTS7
(a disintegrin and metalloprotease with thrombospondin motif
7) gene on chromosome 15q25 and clinical phenotypes of
coronary artery disease (CAD).1–3 One of the lead single
nucleotide polymorphisms (SNPs), rs3825807, is an adenine
(A) to guanine (G) substitution located in exon 4 of the
ADAMTS7 gene, with the G allele conferring a reduced risk of
CAD,1–3 and is found to be in linkage disequilibrium with other
SNPs such as rs19940162 and rs71780514 commonly
studied at the ADAMTS7 loci. This nonsynonymous SNP
leads to an amino acid change in the prodomain of the
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ADAMTS7 protein, a metalloproteinase that plays a role in
proteolysis and degradation of extracellular matrix in connec-
tive tissues.5 Functional studies have revealed that this
substitution affects maturation of ADAMTS7, resulting in
reduced vascular smooth muscle cell migration.6 Further-
more, in vivo animal studies show that ADAMTS7 deﬁciency
confers reduced atherosclerotic lesion formation and neoin-
tima thickening.7,8
These data therefore suggest an important role of normally
functioning ADAMTS7 in driving atherosclerosis and plaque
development. We sought to further explore this hypothesis by
examining whether genetic variation in ADAMTS7 (and
therefore reduced functional activity of the gene product)
would be associated with lower measures of quantiﬁable
atherosclerosis (in vivo and ex vivo) and clinically relevant
outcomes.
Methods
Immunohistochemical Analysis of Ex Vivo Human
Coronary Atherosclerotic Plaques
Human coronary arteries were obtained from authorized
hospital postmortems for research purposes (n=50). DNA was
extracted from tissues using the Wizard Genomic DNA
puriﬁcation kit (Promega).6 Formaldehyde-ﬁxed parafﬁn-
embedded sections were deparafﬁnized, rehydrated, and
incubated in sodium citrate for antigen retrieval. The sections
were then double stained with anti-human smooth muscle a-
actin antibody (Sigma A5691) and anti-human ADAMTS7
antibody (Abcam, ab28557). Morphology of the section was
determined by one investigator (K.C.) in accordance with
standard American Heart Association classiﬁcation.9 These
were independently veriﬁed by an expert pathologist (R.N.P.)
who was blinded to the ﬁndings, with complete agreement.
For American Heart Association type V or VI classiﬁed plaques
(ﬁbroatheromatous), the intima and ﬁbrous cap thicknesses
were measured in the most representative area on a
standardized scale and power ﬁeld. The percentage area of
positive a-actin stain in the intima was calculated in both
ﬁbroatheromatous and ﬁbrous plaques. Calciﬁcation of the
atherosclerotic plaque was assessed as a binary measure—
presence or absence—and by semiquantitative assessment
on a scale of 0 to 3. All measurements were performed using
Image-Pro 7.0.6
Southampton Atherosclerosis Study
Consecutive white patients undergoing interventional or
diagnostic coronary angiography were recruited in the Wessex
Cardiothoracic Unit of the Southampton General Hospital
from 1999 to 2002 as part of the SAS (Southampton
Atherosclerosis Study).10 The study was approved by the local
research ethics committee, and all participants provided
written consent. Demographic and clinical data were recorded
including age, sex, weight, height, occupation, smoking habit,
and number of cigarettes smoked per day by each smoker,
the presence or absence of hyperlipidemia (deﬁned as
cholesterol >5.2 mmol/L and/or triglyceride >3 mmol/L),
current medications particularly the use of statins and
ﬁbrates, hypertension (deﬁned as diastolic blood pressure
>95 mm Hg and/or systolic blood pressure >160 mm Hg),
type 1 or type 2 diabetes mellitus, previous myocardial
infarction (MI), and coronary heart disease in ﬁrst-degree
relatives younger than 65 years. DNA was extracted from
peripheral blood samples using the “salting out” method.11
ADAMTS7 rs3825807 was genotyped as part of the
CARDIoGRAM project using the Sequenom platform.3
Emory Cardiovascular Biobank
The Emory Cardiovascular Biobank (EmCAB) consists of 3600
consecutive patients aged 18 to 90 years, enrolled before
undergoing elective or emergency cardiac catheterization
across 3 Emory Healthcare sites in Atlanta between 2003 and
2009. The study was approved by the institutional review
board of Emory University, Atlanta, GA, and all participants
provided written informed consent. Patients were excluded if
they had a history of heart transplantation. Full details of the
cohort have been previously published.12 Demographic char-
acteristics; risk factors such as hypertension, dyslipidemia,
and diabetes mellitus; and medication usage were recorded.
Laboratory data were collected at the time of enrollment.
Genotyping of SNPs including rs3825807 was performed at
Clinical Perspective
What Is New?
• Variation in the ADAMTS7 gene has been associated with
risk of coronary artery disease; however, its pathological
and clinical consequences have yet to be determined.
• We found that a genetic variant associated with reduced
function of ADAMTS7 is associated with less severe
histological features of human atherosclerotic plaques,
lower angiographic coronary artery disease severity in 2
independent cohorts, and lower risk of incident revascular-
ization during follow-up.
What Are the Clinical Implications?
• These ﬁndings are strongly consistent with the hypothesis
that ADAMTS7 activity promotes atherosclerosis and
therefore may represent a potential pathway for drug
targeting.
DOI: 10.1161/JAHA.117.006928 Journal of the American Heart Association 2
ADAMTS7 and Coronary Artery Disease Chan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 31, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
deCODE genetics in Reykjavik, Iceland, using the Centaurus
(Nanogen) Platform.12
Coronary Angiography Evaluation
Coronary angiograms were systematically characterized by a
consultant cardiologist in SAS. In EmCAB, angiograms were
reported by 2 independent observers with good interobserver
agreement and intraclass correlation coefﬁcient of 0.88 (95%
conﬁdence interval [CI], 0.74–0.95).13 Observers in both
studies were blinded to genotype. The angiogram reports
were then characterized for several anatomic and morpho-
logical criteria: (1) number of major epicardial vessels with
>50% stenosis, where multivessel disease was deﬁned as ≥2
vessels involvement; (2) anatomical location of the lesions
using a 17-segment modiﬁed American Heart Association
model14; and (3) the percentage diameter stenosis for each
lesion graded into <25%, 26% to 50%, 51% to 74%, 75% to
94%, 95% to 99%, and 100% stenosis. Proximal disease was
deﬁned as lesions located in left main, proximal left anterior
descending (LAD), proximal right coronary artery, and prox-
imal left circumﬂex arteries.
A semiquantitative scoring system was used to grade the
angiographic burden of CAD. The Gensini score is a
nonlinear scale weighting lesions by prognostic signiﬁcance,
using location, ranging from 0.5 to 5.0, and degree of
stenosis (<25%=2, 26–50%=4, 51–75%=8, 76–90%=16, 91–
99%=32, and 100%=64); thus, left main and severe proximal
lesions confer higher scores.15 The Sullivan Extent score
quantiﬁes the proportional surface area of the coronary tree
affected by atheroma, with the right coronary artery divided
into 4 segments (25% per segment) and the LAD and left
circumﬂex each divided into 3 segments (33% per
segment).16
In both cohorts, only native vessel disease was scored.
Stented segments were counted as diseased (>75%), while
lesions or stents within arterial or venous grafts were not
included.
Incident Outcomes
Outcome data were available for the EmCAB cohort only.
Patients were followed prospectively for determination of
incident all-cause mortality (deﬁned as death from any cause),
incident nonfatal MI (deﬁned using standard criteria for MI),
and incident coronary artery revascularization (deﬁned as
native vessel revascularization with stenting or ﬁrst coronary
artery bypass grafting). Follow-up was performed by person-
nel blinded to genotype data through telephone interview,
chart review, and linkage with the Social Security Death Index
and State records. Medical records were accessed or
requested to validate all self-reported events. Deﬁnitions
and details about follow-up and outcome ascertainment have
been previously published.17
Statistical Analysis
Continuous variables are presented as means (SDs) and
categorical variables as proportions (percentages) with 1-way
analysis of variance and v2 tests used to determine
differences by genotype. Variables were tested for normality
with Kolmogorov-Smirnov statistics and (+1 natural log)
transformed where appropriate for parametric analyses and
reverse transformed for interpretation of the effect estimate.
Non-normally distributed variables were tested using appro-
priate nonparametric tests (Kruskal–Wallis). Haploview 4.0
(Broad Institute) was used to compute Hardy–Weinberg
equilibrium and minor allele frequency for rs3825807. Power
calculations were performed using G-Power package 3.1
(Heinrich-Heine-Universit€at D€usseldorf).
Logistic and linear regression models were constructed to
test the additive effect of the rs3825807 SNP on CAD
phenotypes including severity and extent, with the SNP coded
as 0, 1, and 2, based on the number of minor alleles (G).
Analyses were repeated after adjustment for traditional risk
factors for CAD including age, sex, smoking status, diabetes
mellitus, and hypertension.
We also conducted a meta-analysis of the summary
estimates for the genotype-CAD association analysis from
each cohort under a random-effects model. We calculated
pooled statistics as odds ratios (ORs) with 95% CIs and overall
z statistics. Cochran’s Q, tau2, and I2 index were used to
assess heterogeneity between the 2 cohorts.
Outcome and survival data were analyzed using Cox
proportional hazards regression models adjusted for age and
sex, and further adjusted for other risk factors including
smoking status, diabetes mellitus, and hypertension. Schoen-
feld residuals were examined to check for violation of the
proportional hazards assumption. Patients with heart trans-
plants or coronary bypass grafting at baseline were excluded
from the outcome analysis. A 2-tailed P<0.05 was considered
signiﬁcant. Statistical analyses were performed using SPSS
version 18.0 (SPSS Inc).
Results
ADAMTS7 Association With Atherosclerotic
Plaque Characteristics
Examining all 50 ex vivo human coronary atherosclerotic
plaques together (mean age of patients 72.211.3 years,
47.6% men, all white), there was no statistically signiﬁcant
association between whole intima or media thickness with the
G allele of the ADAMTS7 SNP (Table 1).
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However, among the 28 plaque samples deemed to be
ﬁbroatheromatous according to American Heart Association
criteria and suitable for further plaque characterization, there
was a signiﬁcant association between the rs3825807 G allele
and reduced ﬁbrous cap thickness (b 88.833.9, P=0.017),
reduced ﬁbrous cap-to-intima thickness (b 0.110.05,
P=0.039), and a lower percentage area a-actin in intima (b
0.080.03, P=0.029) under an additive genetic model
(Table 1 and Figure 1). There were no associations between
the SNP and intima thickness or the extent of plaque
calciﬁcation.
ADAMTS7 Association With CAD
A total of 1359 white patients from SAS and 2684 white
patients from EmCAB were genotyped for the ADAMTS7 SNP
Table 1. Ex Vivo Coronary Atherosclerotic Plaque Characteristics by ADAMTS7 rs3825807 Genotype
All Coronary Plaques (n=50)
ADAMTS7 Genotype
b (SE) P ValueAA (n=22) AG (n=17) GG (n=11)
Whole intima thickness 699.4 (66.8) 793.5 (83.3) 667.8 (75.9) 17.3 (62.6) 0.54
Media thickness 134.6 (13.9) 156.4 (14.9) 167.7 (25.7) 17.1 (12.2) 0.38
AHA Class V or VI Plaques (n=28) AA (n=14) AG (n=9) GG (n=5)
Intima thickness 741.4 (69.4) 712.6 (88.6) 615.8 (67.8) 23.6 (63.1) 0.35
Fibrous cap thickness 329.4 (51.4) 217.0 (36.1) 157.7 (8.8) 88.8 (33.9) 0.017
Fibrous cap:intima thickness ratio 0.47 (0.06) 0.33 (0.06) 0.24 (0.04) 0.11 (0.05) 0.039
Percent area a-actin stain in intima 36.0 (4.51) 29.2 (4.51) 17.0 (1.64) 9.1 (3.5) 0.017
Calcification (binary), % 53.3 26.7 20 0.71
Calcification (quantitative) 1.46 (0.37) 1.00 (0.44) 1.40 (0.40) 0.09 (0.31) 0.78
Coronary plaque features for the 50 ex vivo samples, presented by genotype of rs3825807 single nucleotide polymorphism. Intima, media, and ﬁbrous cap thicknesses were measured in
a.u. and expressed as mean (SEM). Characteristics are also shown for the subset of plaques falling into American Heart Association (AHA) class V or VI ﬁbroatheroma and suitable for
further characterization. Calciﬁcation was characterized as presence or absence (binary) or graded on a scale of 0 to 3 depending on burden of calciﬁcation (quantitative).
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Figure 1. Associations between human atherosclerotic plaque morphology and ADAMTS7 genotypes. A,
Intima thickness, (B) ﬁbrous cap thickness, (C) ﬁbrous cap:intima thickness, (D) percentage a-actin in
intima.* denotes p<0.05
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rs3825807 and included in the analysis. Baseline patient
characteristics for both cohorts are presented in Table 2. The
mean age and proportion of men were similar in both SAS
(62.8 [10.2] years and 70%) and EmCAB (63.8 [11.1] years
and 68%) cohorts. However, there were some differences,
including more smokers and fewer patients with diabetes
mellitus in the SAS cohort (70% and 12%, respectively)
compared with in the EmCAB cohort (60% and 30%, respec-
tively). Signiﬁcant (>50% stenosis) angiographic CAD was
recorded in 79.2% of patients in SAS and 63.7% of patients in
EmCAB, with the remainder having normal or nonobstructive
disease. The observed genotype frequencies were consistent
with Hardy–Weinberg equilibrium, and the minor allele
frequency for rs3825807 was 0.43 for both cohorts, similar
to previously published reports.1
The G allele of the ADAMTS7 SNP was associated with a
protective effect on CAD in both cohorts, with a 16% to 19%
lower odds of disease per allele after adjustment for age and
sex (SAS: OR, 0.81 [95% CI, 0.67–0.98]; EmCAB: OR, 0.84
[95% CI, 0.75–0.95]). These estimates persisted after adjust-
ment for further CAD risk factors. Consistent with prior
reports, there was no signiﬁcant association between the G
allele and MI (SAS: OR, 1.01 [95% CI, 0.86–1.18]; EmCAB: OR,
0.85 [95% CI, 0.70–1.02]).
Similarly, we found that in both cohorts, the G allele was
modestly associated with lower odds of multiple-vessel
disease (SAS: OR, 0.86 [95% CI, 0.74–1.00]; EmCAB: 0.81
[95% CI ,0.72–0.92]), as well as LAD disease (SAS: OR, 0.84
[95% CI, 0.72–0.98]; EmCAB: OR, 0.80 [95% CI, 0.71–0.89]) in
both cohorts, and with proximal disease in EmCAB (Table 3).
Combining data for both cohorts through meta-analysis
revealed that the G allele conferred a pooled OR of 0.84 (95%
CI, 0.77–0.93) for obstructive CAD, 0.85 (95% CI, 0.78–0.93)
for multivessel disease, 0.83 (95% CI, 0.76–0.91) for LAD
disease, and 0.84 (95% CI, 0.76–0.93) for proximal disease
(Figure S1). There was no signiﬁcant heterogeneity Tau2 and
I2=0% between the cohorts for the pooled analyses.
In addition, we identiﬁed an association between the G
allele of the ADAMTS7 SNP and semiquantitative angiographic
scores. In both cohorts, there was an 5-point reduction in
median Gensini score and a 10-point reduction in median
Sullivan score between those with 2 copies of the G allele
compared with those with none. Clinically, this difference can
be interpreted as equivalent to, for example, a 50% discrete
lesion in the proximal LAD (Gensini score=5) or detectable
atheroma affecting half of the right coronary artery (Sullivan
score=10). After adjustment for age and sex, the Gensini
score was lower for each copy of the G allele in both SAS
(P=0.026) and EmoryCAB (P<0.001), while Sullivan Extent
score was also similarly lower in both cohorts (SAS P=0.029,
EmCAB P<0.001). These associations persisted after adjust-
ment for further risk factors (Table 4).
Table 2. Patient Characteristics by ADAMTS7 rs3825807 Genotype
Patient Characteristics Total
SAS
P Value Total
EmCAB
P Value
ADAMTS7 Genotype ADAMTS7 Genotype
AA AG GG AA AG GG
No. 1359 472 595 292 2684 858 1336 490
Age, y 62.5 (10.3) 62.2 (10.5) 62.8 (10.2) 62.2 (10.2) 0.63 63.8 (11.4) 63.9 (11.1) 64.0 (11.5) 63.3 (11.6) 0.56
Men, % 70.1 67.8 71.3 71.2 0.42 67.7 66.0 67.7 71.1 0.15
Body mass index,
kg/m2
27.6 (4.4) 27.8 (4.4) 27.5 (4.4) 27.5 (4.4) 0.41 29.4 (6.1) 29.6 (6.2) 29.4 (6.2) 29.0 (5.8) 0.32
Diabetes mellitus, % 11.8 13.9 11.1 9.6 0.17 30.2 30.2 30.2 29.9 0.99
Hypertension, % 42.6 40.9 44.8 40.6 0.36 68.3 68.0 68.5 68.4 0.97
Hypercholesterolemia,
%
79.2 82.2 78.0 77.1 0.14 70.0 70.7 69.1 71.3 0.59
Smoker, % 72.3 74.3 70.6 72.5 0.41 60.5 58.5 61.4 61.3 0.37
Statin use, % 49.1 45.1 51.4 50.7 0.10 24.9 24.3 25.3 24.5 0.86
Prior myocardial
infarction, %
38.4 37.2 38.8 39.5 0.83 33.7 33.0 33.6 34.9 0.77
Normal coronaries, % 20.8 19.7 19.2 26.0 0.04 27.7 23.4 28.9 32.4 0.001
Angiographic
CAD >50%, %
79.2 78.5 80.4 72.8 0.05 63.7 67.7 63.2 59.4 0.02
Data are presented as mean (SD) or percentage unless indicated by rs3825807 genotype for each study. CAD indicates coronary artery disease; EmCAB, Emory Cardiovascular Biobank;
SAS, Southampton Atherosclerosis Study.
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Effect of ADAMTS7 on Cardiovascular Outcomes
Within the EmCAB cohort, after excluding those with prior
coronary artery bypass grafting or heart transplants, 1929
patients with available follow-up data were included in the
outcome analysis, with a median follow-up of 3.02.3 years.
During this time, there were 184 (9.5%) all-cause deaths, 68
(3.5%) MI events, and 114 (5.9%) revascularization proce-
dures. Cox regression analysis adjusted for traditional risk
factors showed that there was no signiﬁcant association for
all-cause mortality (hazard ratio, 1.13; 95% CI, 0.94–1.38) or
MI (hazard ratio, 0.85; 95% CI, 0.61–1.18) during the follow-
up period (Table 5). However, each additional G allele
conferred a signiﬁcantly lower risk of incident native vessel
revascularization (hazard ratio, 0.76; 95% CI, 0.59–0.98)
(Figure 2).
Discussion
In this study, using (1) histological samples, (2) coronary
angiographic phenotypes, and (3) clinical outcomes data, we
demonstrate that a nonsynonymous SNP resulting in loss of
function of ADAMTS7 is associated with reduced CAD burden.
Collectively, our ﬁndings provide further support for the
emerging role of this protease in promoting atherosclerosis.
Early genome-wide association studies ﬁrst identiﬁed
variants in the ADAMTS7 gene as associating with prevalent
CAD and MI. In an important analysis, Reilly et al2 identiﬁed
this variant as associating with CAD but not MI, suggesting
that the gene primarily drives atherosclerosis as its mecha-
nism of risk. The adenine (A) to guanine (G) substitution of
rs3825807 results in a serine-to-proline substitution in the
prodomain of ADAMTS7,6 and functional studies using
cultured vascular smooth muscle cell model have revealed
that this affects ADAMTS7 function not by inﬂuencing its
expression but rather its maturation and thrombospondin-5
cleavage.6 Recent in vivo studies using ADAMTS7-null knock-
out mouse models have shown that ADAMTS7/ mice have
less signiﬁcant neointima thickening, likely through reduced
vascular smooth muscle cell migration.8 Normally functioning
ADAMTS7 might also impair re-endothelialization by degrad-
ing thrombospondin-1, thereby inhibiting endothelial cell
proliferation and migration.18 These results thus indicate that
ADAMTS7 may ordinarily promote atherosclerosis while
impairment of this protein could halt the atherosclerotic
process. However, this has not yet been assessed with
detailed in vivo or ex vivo measures of atherosclerosis in
humans.
Table 3. Association Between Genetic Variation at ADAMTS7
(rs3825807) and Binary CAD Phenotypes
OR (95% CI)* Adjusted OR (95% CI)†
Obstructive CAD
SAS 0.81 (0.67–0.98) 0.82 (0.67–0.99)
EmCAB 0.84 (0.75–0.95) 0.84 (0.74–0.95)
Multivessel disease
SAS 0.86 (0.74–1.00) 0.87 (0.74–1.02)
EmCAB 0.81 (0.72–0.92) 0.82 (0.73–0.93)
LAD disease
SAS 0.84 (0.72–0.98) 0.84 (0.71–0.98)
EmCAB 0.80 (0.71–0.89) 0.81 (0.72–0.91)
Proximal disease
SAS 0.92 (0.75–1.13) 0.86 (0.69–1.07)
EmCAB 0.80 (0.72–0.90) 0.80 (0.71–0.90)
Odds ratio (OR) with 95% conﬁdence interval (CI) derived for association between the G
allele of rs3825807 and obstructive coronary artery disease (CAD) vs no CAD,
multivessel disease vs single-vessel disease; left anterior descending (LAD) disease vs
non-LAD disease, and proximal disease vs distal disease. EmCAB indicates Emory
Cardiovascular Biobank; SAS, Southampton Atherosclerosis Study.
*Adjusted for age and sex only.
†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus.
Table 4. Association Between Genetic Variation at ADAMTS7 (rs3825807) and Angiographic CAD Scores
Angiographic Scores
ADAMTS7 Genotype
b (SE) P Value* P Value†AA AG GG
Gensini
SAS 26.3 (7–57) 28 (7–57) 20 (2–52) 0.12 (0.06) 0.026 0.049
EmCAB 15 (15–63) 11 (0–48) 10 (0–44) 0.18 (0.05) <0.001 <0.001
Sullivan
SAS 40 (20–50) 40 (20–50) 30 (20–50) 0.09 (0.05) 0.029 0.053
EmCAB 40 (20–60) 35 (0–60) 30 (0–55) 0.15 (0.04) <0.001 <0.001
CAD indicates coronary artery disease; EmCAB, Emory Cardiovascular Biobank; SAS, Southampton Atherosclerosis Study.
*Adjusted for age and sex only.
†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus; b (SE) for the ln+1 transformed values.
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In an analysis of the MESA (Multi-Ethnic Study of
Atherosclerosis) cohort, an association was reported between
a different SNP in ADAMTS7 and coronary artery calciﬁcation,
but only in a Hispanic population subset, and no association
was found with carotid intima-media thickness.19 Similarly,
ADAMTS7 was not associated with carotid intima-media
thickness in Spanish patients with rheumatoid arthritis.20 A
positive association with CAD was, however, recently reported
in a Chinese cohort using angiographic data, although the
association was modest, used broad phenotypic deﬁnitions,
was restricted to a Chinese population, and was not replicated
in a smaller Portuguese study.21
Study Strengths and Limitations
Our study builds on some of these reports and adds important
novel data. First, using ex vivo plaque samples, we show that
with each G allele there is a trend to lower intima-media
thickness and other plaque characteristics indicative of
atheroma development. Second, using clinical coronary
angiographic data, we demonstrate that each copy of the G
allele confers lower odds of having both obstructive disease
and severe manifestations of CAD such as multivessel and
proximal disease. This is also reﬂected with lower semiquan-
titative scores of CAD burden, a more reﬁned and validated
phenotype using Gensini and Sullivan scoring systems.12
We also conﬁrmed that while ADAMTS7 variation was
associated with CAD, it was not associated with MI per se,
using the approach described by Reilly et al.2 This has been
used as evidence that ADAMTS7 confers risk through
atherosclerosis and not by plaque rupture or thrombotic
mechanisms, which may drive an MI. To further explore this
hypothesis, we examined the association with incident
outcomes and found that the protective G allele of the
ADAMTS7 variant did not impact rates of all-cause death or
MI. This is in line with a recent study of 1100 patients with
known CAD, in whom no association was found with the same
SNP and all-cause mortality over a median of 5 years,
although there was an association with cardiovascular death
(P=0.025).22 Intriguingly, in our study, where nonfatal events
were also available, the rate of native vessel revascularization
following enrollment was signiﬁcantly lower in those carrying
the protective allele, an indirect reﬂection of lower atheroma
development and progression, and again supporting the
concept that ADAMTS7 ordinarily drives progressive
atherosclerosis.
Finally, a recent study reported that of the 45 loci known
to associate with CAD risk, a variant at ADAMTS7
rs7178051, which is in modest linkage disequilibrium with
rs3825807 (LD=0.52), exhibited an important gene-smoking
interaction in 61 000 cases with coronary heart disease and
80 000 controls.4 The protective effect of ADAMTS7 genetic
Table 5. Association Between Genetic Variation at ADAMTS7 (rs3825807) and Incident Outcomes in the EmCAB Cohort
Events, No. (%)
ADAMTS7 Genotype
HR (95% CI)* HR (95% CI)†AA AG GG
All-cause mortality 73 (12.3) 116 (12.4) 43 (12.5) 1.12 (0.92–1.35) 1.13 (0.94–1.38)
Myocardial infarction 29 (4.9) 39 (4.2) 10 (3.0) 0.84 (0.60–1.17) 0.85 (0.61–1.18)
Revascularization 50 (8.4) 67 (7.2) 14 (4.2) 0.77 (0.60–0.98) 0.76 (0.59–0.98)
Hazard ratio (HR) and 95% conﬁdence interval (CI) shown for the association between the G allele of rs3825807 and risk of incident events. EmCAB indicates Emory Cardiovascular
Biobank.
*Adjusted for age and sex only.
†Adjusted for age, sex, smoking status, hypertension, and diabetes mellitus.
Figure 2. Association between genetic variation at ADAMTS7
(rs3825807) and incident revascularization events in the Emory
Cardiovascular Biobank (EmCAB) cohort. Kaplan–Meier curve
showing association between ADAMTS7 genotype and risk of
incident native vessel revascularization (percutaneous or surgical
coronary intervention), among participants within the EmCAB
cohort. Genotype GG=blue; AG=green; AA=red.
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variation on CAD risk was found to be lower in persons who
smoked than in nonsmokers, while exposure of human
coronary cell lines to cigarette smoke led to induction of
ADAMTS7 activity. We examined this observation in our study
and while there were some nonsigniﬁcant trends, we were
unable to identify any signiﬁcant interactions or differences in
association between the rs3825807 SNP and CAD pheno-
types among smokers and nonsmokers (Tables S1 through
S3). However, it is worth noting that our study was within two
cohorts with coronary heart disease, rather than a case-
control design with coronary heart disease–free controls.
Thus a much higher prevalence of smoking in our cohort
(64.4% versus 56.9%) and smaller overall sample size (3981
versus 141 162) might have contributed to the lack of
interactions with smoking found in the current study.
Nonetheless, we believe our ﬁndings are complementary to
the narrative emerging on the atherogenic role of ADAMTS7.
Our study is unique in that we were able to draw on several
complementary sources of data and phenotypes related to
atherosclerosis, overcoming limitations associated with each
individually. Despite our consistent and promising ﬁndings,
some limitations need to be considered. First, only a small
number of ex vivo samples were available to study and these
may have been prone to measurement error despite attempts
to reduce potential variation with a priori measurement
standard. Second, there is a degree of selection bias with
both SAS and EmCAB cohorts enrolling only those undergoing
coronary angiography and with CAD, which could have
distorted genotype distribution. However, allele frequency
was similar to those reported in general populations,
suggesting that this was not likely to have been a major
factor. Finally, the association with revascularization, while
exciting and supportive of the overall hypothesis, should be
interpreted with caution given these data were from a single
center and revascularization as an end point is susceptible to
clinical practice variation. However, together, our data provide
consistent evidence for the role of ADAMTS7 in promoting
atherosclerosis.
Conclusions
Genetic variation at the ADAMTS7 locus is associated with
several complementary CAD phenotypes. Collectively, these
ﬁndings support the emerging role of ADAMTS7 in promoting
atherosclerosis and may represent a potential antiatheroscle-
rosis drug target.
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Table S1. Association between genetic variation at ADAMTS7 (rs3825807) and obstructive CAD 
phenotype stratified by smoking status 
Presence of CAD n OR (95% CI)* p value* Interaction p value 
SAS     
Ever-smoked 974 0.98 (0.75-1.27) 0.85 
0.92 
Never-smoked 373 0.73 (0.52-1.01) 0.06 
     
EmCAB     
Ever-Smoked 1593 0.80 (0.68-0.94) 0.01 
0.63 
Never-Smoked 1041 0.84 (0.70-1.01) 0.07 
 
Odds ratio (OR) with 95% confidence interval (95% CI) derived for association between the G allele 
of rs3825807 and obstructive CAD vs no CAD, stratified by smoking status. *adjusted for age and sex.  
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Table S2. Association between genetic variation at ADAMTS7 (rs3825807) and angiographic CAD 
scores stratified by smoking status   
Angiographic 
scores 
 n β (SE) p-value* 
Interaction 
p-value 
Gensini 
Score 
SAS 
Ever-smoked 974 -0.12 (0.06) 0.048 
0.11 
Never-smoked 373 -0.14 (0.11) 0.21 
Emory CAB 
Ever-smoked 1593 -0.19 (0.06) 0.002 
0.35 
Never-smoked 1041 -0.14 (0.08) 0.08 
       
Sullivan 
Extent Score 
SAS 
Ever-smoked 974 -0.09 (0.04) 0.037 
0.15 
Never-smoked 373 -0.08 (0.08) 0.28 
Emory CAB 
Ever-smoked 1593 -0.15 (0.05) 0.002 
0.94 
Never-smoked  1041 -0.13 (0.06) 0.04 
 
SAS - Southampton Atherosclerosis Study; EmCAB – Emory Cardiovascular Biobank; CAD – Coronary 
Artery Disease; β (SE) for the ln+1 transformed value; *adjusted for age and sex.  P-value interaction 
analysed using general linear model (univariate) 
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Table S3. Association between genetic variation at ADAMTS7 (rs3825807) and incident outcomes 
in the EmCAB cohort stratified by smoking status 
 
 
Ever-smoked 
(n=1115) 
Non-smoker 
(n=783) 
 
 HR (95% CI)* HR (95% CI)* 
P for 
interaction  
All-cause 
mortality  
1.27 (1.00-
1.59) 
0.89 (0.64-
1.25) 
0.11 
    
MI 
0.97 (0.64-
1.47) 
0.65 (0.38-
1.12) 
0.24 
    
Revascularization 
0.73 (0.53-
0.99)  
0.85 (0.55-
1.32) 
0.57 
    
 
Hazard Ratio (HR) and 95% Confidence Interval (CI) shown for association between the G allele of 
rs3825807 and risk of incident events, stratified by smoking status; *adjusted for age and sex only;  
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Figure S1. Meta-analysis with pooled estimates for association between genetic variation at 
ADAMTS7 (rs3825807) and CAD phenotypes  
 
 
 
Meta-analysis of association between the G allele of rs3825807 and CAD phenotypes, under an 
additive genetic model 
SAS - Southampton Atherosclerosis Study; EmCAB – Emory Cardiovascular Biobank; CAD – Coronary 
Artery Disease; LAD – Left Anterior Descending 
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